vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and loanDepot, Inc. (LDI). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -7.2%, a 6.5% gap on every dollar of revenue. On growth, loanDepot, Inc. posted the faster year-over-year revenue change (20.5% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-648.0M). Over the past eight quarters, loanDepot, Inc.'s revenue compounded faster (18.0% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
AVNS vs LDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $310.3M |
| Net Profit | $-1.3M | $-22.5M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | -10.3% |
| Net Margin | -0.7% | -7.2% |
| Revenue YoY | 0.7% | 20.5% |
| Net Profit YoY | 99.7% | 32.4% |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $310.3M | ||
| Q3 25 | $177.8M | $323.3M | ||
| Q2 25 | $175.0M | $282.5M | ||
| Q1 25 | $167.5M | $273.6M | ||
| Q4 24 | $179.6M | $257.5M | ||
| Q3 24 | $170.4M | $314.6M | ||
| Q2 24 | $171.7M | $265.4M | ||
| Q1 24 | $166.1M | $222.8M |
| Q4 25 | $-1.3M | $-22.5M | ||
| Q3 25 | $-1.4M | $-4.9M | ||
| Q2 25 | $-76.8M | $-13.4M | ||
| Q1 25 | $6.6M | $-21.9M | ||
| Q4 24 | $-397.3M | $-33.2M | ||
| Q3 24 | $4.3M | $1.4M | ||
| Q2 24 | $1.8M | $-32.2M | ||
| Q1 24 | $-900.0K | $-34.3M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | -10.3% | ||
| Q3 25 | 0.1% | -3.2% | ||
| Q2 25 | -42.6% | -11.4% | ||
| Q1 25 | 6.1% | -16.8% | ||
| Q4 24 | -233.0% | -32.7% | ||
| Q3 24 | 7.0% | 1.1% | ||
| Q2 24 | 3.7% | -29.1% | ||
| Q1 24 | 2.4% | -38.2% |
| Q4 25 | -0.7% | -7.2% | ||
| Q3 25 | -0.8% | -1.5% | ||
| Q2 25 | -43.9% | -4.7% | ||
| Q1 25 | 3.9% | -8.0% | ||
| Q4 24 | -221.2% | -12.9% | ||
| Q3 24 | 2.5% | 0.4% | ||
| Q2 24 | 1.0% | -12.1% | ||
| Q1 24 | -0.5% | -15.4% |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | $0.01 | ||
| Q2 24 | $0.04 | $-0.18 | ||
| Q1 24 | $-0.02 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $337.2M |
| Total DebtLower is stronger | $90.3M | $2.1B |
| Stockholders' EquityBook value | $778.2M | $386.0M |
| Total Assets | $1.1B | $6.9B |
| Debt / EquityLower = less leverage | 0.12× | 5.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $337.2M | ||
| Q3 25 | $70.5M | $459.2M | ||
| Q2 25 | $90.3M | $408.6M | ||
| Q1 25 | $97.0M | $371.5M | ||
| Q4 24 | $107.7M | $421.6M | ||
| Q3 24 | $89.0M | $483.0M | ||
| Q2 24 | $92.2M | $533.2M | ||
| Q1 24 | $75.8M | $603.7M |
| Q4 25 | $90.3M | $2.1B | ||
| Q3 25 | $93.4M | $2.1B | ||
| Q2 25 | $95.7M | $2.1B | ||
| Q1 25 | $98.0M | $2.0B | ||
| Q4 24 | $125.3M | $2.0B | ||
| Q3 24 | $152.6M | $2.0B | ||
| Q2 24 | $164.9M | $2.0B | ||
| Q1 24 | $167.2M | $2.3B |
| Q4 25 | $778.2M | $386.0M | ||
| Q3 25 | $778.0M | $433.3M | ||
| Q2 25 | $776.3M | $439.1M | ||
| Q1 25 | $839.4M | $469.3M | ||
| Q4 24 | $828.5M | $506.6M | ||
| Q3 24 | $1.2B | $592.0M | ||
| Q2 24 | $1.2B | $578.9M | ||
| Q1 24 | $1.2B | $637.3M |
| Q4 25 | $1.1B | $6.9B | ||
| Q3 25 | $1.1B | $6.2B | ||
| Q2 25 | $1.0B | $6.2B | ||
| Q1 25 | $1.1B | $6.4B | ||
| Q4 24 | $1.2B | $6.3B | ||
| Q3 24 | $1.7B | $6.4B | ||
| Q2 24 | $1.7B | $5.9B | ||
| Q1 24 | $1.7B | $6.2B |
| Q4 25 | 0.12× | 5.44× | ||
| Q3 25 | 0.12× | 4.83× | ||
| Q2 25 | 0.12× | 4.70× | ||
| Q1 25 | 0.12× | 4.30× | ||
| Q4 24 | 0.15× | 4.00× | ||
| Q3 24 | 0.12× | 3.31× | ||
| Q2 24 | 0.13× | 3.41× | ||
| Q1 24 | 0.14× | 3.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-638.7M |
| Free Cash FlowOCF − Capex | $21.3M | $-648.0M |
| FCF MarginFCF / Revenue | 11.8% | -208.9% |
| Capex IntensityCapex / Revenue | 3.8% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-734.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-638.7M | ||
| Q3 25 | $14.0M | $43.4M | ||
| Q2 25 | $6.8M | $67.6M | ||
| Q1 25 | $25.7M | $-179.9M | ||
| Q4 24 | $57.9M | $47.7M | ||
| Q3 24 | $23.0M | $-349.2M | ||
| Q2 24 | $27.8M | $-278.3M | ||
| Q1 24 | $-8.0M | $-278.5M |
| Q4 25 | $21.3M | $-648.0M | ||
| Q3 25 | $7.0M | $38.7M | ||
| Q2 25 | $-4.2M | $61.4M | ||
| Q1 25 | $19.0M | $-186.7M | ||
| Q4 24 | $53.1M | $40.8M | ||
| Q3 24 | $20.0M | $-356.4M | ||
| Q2 24 | $21.9M | $-285.7M | ||
| Q1 24 | $-12.1M | $-283.3M |
| Q4 25 | 11.8% | -208.9% | ||
| Q3 25 | 3.9% | 12.0% | ||
| Q2 25 | -2.4% | 21.7% | ||
| Q1 25 | 11.3% | -68.2% | ||
| Q4 24 | 29.6% | 15.8% | ||
| Q3 24 | 11.7% | -113.3% | ||
| Q2 24 | 12.8% | -107.7% | ||
| Q1 24 | -7.3% | -127.2% |
| Q4 25 | 3.8% | 3.0% | ||
| Q3 25 | 3.9% | 1.5% | ||
| Q2 25 | 6.3% | 2.2% | ||
| Q1 25 | 4.0% | 2.5% | ||
| Q4 24 | 2.7% | 2.7% | ||
| Q3 24 | 1.8% | 2.3% | ||
| Q2 24 | 3.4% | 2.8% | ||
| Q1 24 | 2.5% | 2.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | -255.05× | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
LDI
Segment breakdown not available.
